The effect of tablet computer-based telemonitoring added to an established telephone disease management program on heart failure hospitalizations: The Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) III Randomized Controlled Trial - 03/05/23
, Susan Parker, RN b, Douglas Gregory, PhD c, Benjamin Koethe, MS d, Amanda R. Vest, MBBS, MPH a, Ayan R. Patel, MD a, Michael S. Kiernan, MD a, David DeNofrio, MD a, Eric Davidson, MD e, Sharanya Mohanty, MD a, Patrick Arpin, DO a, Nicole Strauss, MPH a, Crystal Sommer, MS a, Linda Brandon, RN b, Rita Butler, MD a, Henry Dwaah, BA f, Hilary Nadeau, RN b, Michael Cantor, MD, JD b, Marvin A. Konstam, MD aAbstract |
Background |
Mobile health applications are becoming increasingly common. Prior work has demonstrated reduced heart failure (HF) hospitalizations with HF disease management programs; however, few of these programs have used tablet computer-based technology.
Methods |
Participants with a diagnosis of HF and at least 1 high risk feature for hospitalization were randomized to either an established telephone-based disease management program or the same disease management program with the addition of remote monitoring of weight, blood pressure, heart rate and symptoms via a tablet computer for 90 days. The primary endpoint was the number of days hospitalized for HF assessed at 90 days.
Results |
From August 2014 to April 2019, 212 participants from 3 hospitals in Massachusetts were randomized 3:1 to telemonitoring-based HF disease management (n = 159) or telephone-based HF disease management (n = 53) with 98% of individuals in both study groups completing the 90 days of follow-up. There was no significant difference in the number of days hospitalized for HF between the telemonitoring disease management group (0.88 ± 3.28 days per patient-90 days) and the telephone-based disease management group (1.00 ± 2.97 days per patient-90 days); incidence rate ratio 0.82 (95% confidence interval, 0.43-1.58; P = .442).
Conclusions |
The addition of tablet-based telemonitoring to an established HF telephone-based disease management program did not reduce HF hospitalizations; however, study power was limited
Il testo completo di questo articolo è disponibile in PDF.Mappa
| ClinicalTrials.gov identifier: NCT02084992. Registered on 10 March 2014. |
Vol 260
P. 90-99 - giugno 2023 Ritorno al numero
Articolo precedente
- External validation of bleeding risk models for the prediction of long-term bleeding risk in patients with established cardiovascular disease
- Maria C. Castelijns, Steven H.J. Hageman, Martin Teraa, Manon G. van der Meer, Jan Westerink, Francesco Costa, Jurriën M. ten Berg, Frank L.J. Visseren, UCC-SMART study group
- Postoperative pericardial effusion, pericardiotomy, and atrial fibrillation: An explanatory analysis of the PALACS trial
- Lisa Q. Rong, Antonino Di Franco, Mohamed Rahouma, Arnaldo Dimagli, June Chan, Alexandra J. Lopes, Jiwon Kim, Tommaso Sanna, Richard B. Devereux, Victoria Delgado, Jonathan W. Weinsaft, Filippo Crea, John H. Alexander, Marc Gillinov, John Michael DiMaio, Kane O. Pryor, Leonard Girardi, Mario Gaudino
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?